ClinicalTrials.gg
RecruitingNCT06370182ATHENAUpdated Dec 11, 2025

Safety and Effectiveness of Mechanical Thrombectomy Using the Anaconda ANA Funnel Catheter

An interventional study of ANA Funnel Catheter and Control in Acute Ischemic Stroke From Large Vessel Occlusion, sponsored by Anaconda Biomed S.L.. Recruiting at 22 sites in 5 countries. Open to participants aged 22 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-12-11.

Sponsored by Anaconda Biomed S.L. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
327
Allocation
Randomized
Ages
22 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 480 studies in Ischemic Stroke with a site in United States — 120 open to participants now, 145 under way, 13 of them phase 3. Ischemic Stroke · United States.

Planned enrollment
74th of 364
327 · median 65
Started
2024
with 30 others
No phase
183 of 480
51 open now
Primary completion
2027-08
later than 70 of 144 live
Registered
410th of 480
by date

Among the 480 studies in Ischemic Stroke with a site in United States, this one is the 74th largest by planned enrollment of the 364 interventional ones that give a count, is one of 31 that started in 2024, is one of 183 with no phase, reaches primary completion later than 70 of the 144 other live ones, and was the 410th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

120 of the 480 studies in Ischemic Stroke with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 22 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 480 studies in Ischemic Stroke with a site in United States, or all of them as a file.
02

Study summary

The objective of this study is to assess the safety and effectiveness of mechanical thrombectomy (MT) using the ANA funnel catheter in its intended use, which is to facilitate the navigation and deployment of other neurovascular devices and to allow flow arrest during mechanical thrombectomy procedures performed in subjects experiencing acute ischemic stroke (AIS) secondary to large vessel occlusion (LVO) and treated within 24 hours of symptom onset.

Read the detailed description

Similar to other ancillary devices used in MT, the ANA device is designed to facilitate the delivery of stent retrievers and other catheters during these procedures. Its design aims to enhance procedural success and the efficiency of stent retriever-based MT by enabling flow arrest during clot retrieval. This approach has been shown to improve rates of revascularization and favorable clinical outcomes at three months.

The use of the ANA to facilitate MT with a stent retriever may provide a simplified approach to flow restriction and could achieve acute reperfusion outcomes comparable to commonly used strategies that combine direct aspiration with an intermediate catheter to actuate clot retrieval with a SR.

A dual-arm, prospective, randomized study will be conducted to demonstrate the safety and effectiveness of ANA compared to a conventional approach using cleared stent retrievers for MT. The study will report acute reperfusion success after a single thrombectomy pass with three of the most commonly employed stent retrievers: Solitaire, Trevo, and pRESET. Procedural safety will be assessed by comparing the rate of procedure-related sICH within 24 hours of the intervention between study arms.

03

Conditions studied

  • Acute Ischemic Stroke From Large Vessel Occlusion

Browse trials for

Keywords

  • flow arrest
  • flow restriction
  • funnel
  • guide catheter
  • mechanical thrombectomy
04

Who can participate

Ages eligible
22 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

Subjects meeting all inclusion criteria will be considered for enrollment in the study.

  1. Age 22 to 85 years.
  2. was obtained from subject or acceptable subject surrogate (e.g., next of kin, or legal representative).
  3. A new focal disabling neurologic deficit consistent with acute cerebral ischemia.
  4. Baseline NIHSS obtained prior to procedure ≥ 6 points and ≤ 25 points.
  5. Pre-ictal mRS score of 0,1 or 2.
  6. Treatable within 16 hours of symptom onset, defined as point in time when the subject was last observed to be asymptomatic; treatment start is defined by arterial puncture time.
  7. If indicated, thrombolytic therapy shall be initiated per the institution's usual care and the most recent version of the AHA/ASA Guidelines. Subjects eligible for IV thrombolysis should receive it without delay.
  8. Occlusion (eTICI ≤ 1 flow) of the terminal carotid artery, middle cerebral artery M1 segment or, dominant or proximal M2 segment, indicated for mechanical thrombectomy, confirmed with conventional angiography or CTA/MRA.
  9. Imaging criteria:

    • Perfusion weighted criterion: volume of diffusion restriction visually assessed

      ≤ 50 mL on CTP/MRP, or

    • CT criterion: Alberta Stroke program early CT score (ASPECTS) 6 to 10 on baseline CT/DWI-MRI. (Inclusion of subjects with ASPECTS 5 is permitted at centers performing scoring on MRI)
  10. The subject is indicated for a neurovascular thrombectomy procedure with an approved stent retriever per its Instructions for Use.

Key Exclusion Criteria:

Subjects who meet any of the exclusion criteria will be ineligible for participation in the study.

The following exclusion criteria will be assessed pre-operatively:

  1. Subject was diagnosed with a stroke in the past year.
  2. Clinical symptoms suggestive of bilateral stroke or stroke in multiple territories.
  3. Known hemorrhagic diathesis, coagulation factor deficiency, oral anticoagulant therapy with antivitamin K, with >3.0, or thrombocytopenia - baseline count \< 50,000 platelets/mL.
  4. Known baseline glucose of \<50 mg/dL or >400 mg/dL.
  5. Severe, sustained uncontrolled hypertension to treatment (systolic blood pressure >185 mmHg or diastolic blood pressure >110 mmHg).
  6. Serious, advanced, or terminal disease with anticipated of less than 1 year.
  7. Known cancer with .
  8. History of life-threatening allergy (more than rash) to contrast medium.
  9. Known renal insufficiency with creatinine ≥3 mg/dL or (GFR) \<30 mL/min.
  10. Subject is a current user or has a recent history of cocaine \&/or heroin use.
  11. Known pregnancy and/or lactating female.
  12. Subject is participating in a concurrent study involving an drug or device that would impact the primary endpoint of this study.
  13. Subject is unlikely to be available for a 90-day follow-up (e.g. no fixed home address, visitor from overseas, etc.)
  14. CT or MRI evidence of hemorrhage (the presence of microbleeds is allowed).
  15. Significant mass effect with midline shift.
  16. Evidence of intracranial tumor (except asymptomatic meningioma of ≤ 2cm in diameter).
  17. Suspicion of aortic dissection, presumed septic embolus, or suspicion of bacterial endocarditis.
  18. History of preexisting stent proximal to or at the occlusion site that may preclude safe deployment or recovery of the stent retriever.
  19. Vessel tortuosity too difficult to allow endovascular access of the intracranial ICA per investigator judgement. Indicators of vessel tortuosity include but are not limited to the presence of carotid loops and type 3 aortic arches.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
327 participants (estimated)

Study arms

  • Experimental
    ANA Funnel Catheter Group

    Mechanical thrombectomy using a stent retriever delivered by the ANA device.

    Device: ANA Funnel Catheter

  • Active comparator
    Control Group

    Mechanical thrombectomy using a stent retriever delivered by an approved guide catheter.

    Device: Control

Interventions

  • DeviceANA Funnel Catheter

    Mechanical thrombectomy using a stent retriever delivered by the ANA device that enables local flow restriction when deployed.

  • DeviceControl

    Mechanical thrombectomy using a stent retriever delivered by an approved guide catheter with or without an intermediate catheter and aspiration per conventional techniques.

06

What researchers measure

Primary outcomes

  1. Proportion of subjects with "near-complete" reperfusion after one thrombectomy pass (FPE, eTICI 2c-3, extended Thrombolysis in Cerebral Infarction scale) in the target vessel.

    Reperfusion (eTICI 2c-3) to be assessed by an independent Core Lab.

    Time frame: intra-operative

  2. Rate of symptomatic intracranial hemorrhage (sICH), attributable to the device or procedure.

    Extent of hemorrhage to be assessed by an independent Core Lab, symptoms to be assessed by the Data Monitoring Committee (DMC).

    Time frame: Within 24 hours of the procedure

07

Study locations

22 of 22 sites recruiting
  • Baptist Health Medical Center
    Jacksonville, Florida 32207, United States
    Recruiting
    • · Contact(+1) 904-487-2469
    • Ricardo Hanel · Principal investigator
  • Grady Memorial Hospital, Emory
    Atlanta, Georgia 30322, United States
    Recruiting
    • · Contact(404) 778-1700
    • Diogo Haussen · Principal investigator
  • Advocate Health
    Park Ridge, Illinois 60068, United States
    Recruiting
    • · Contact847-430-6108
    • Demetrius Lopes · Principal investigator
  • University of Iowa
    Iowa City, Iowa 52242, United States
    Recruiting
    • · Contact319-353-6629
    • Edgar Samaniego · Principal investigator
  • Boston Medical Center
    Boston, Massachusetts 02118, United States
    Recruiting
    • · Contact617-638-6609
    • Mohamad Abdalkader · Principal investigator
  • University of Buffalo Neurosurgery
    Buffalo, New York 14203, United States
    Recruiting
    • · Contact716-218-1000
    • Rosalind Lai · Principal investigator
  • Mount Sinai Hospital
    New York, New York 10029, United States
    Recruiting
    • · Contact(+1)7634969283
    • Shahram Majidi · Principal investigator
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
    Recruiting
    • · Contact503-494-8450
    • Scott Rewinkel · Principal investigator
  • University of Pittsburg Medical Center
    Pittsburgh, Pennsylvania 15213, United States
    Recruiting
    • Alhamza Al-Bayati · Principal investigator
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
    Recruiting
    • · Contact615-322-7417
    • Michael Froehler · Principal investigator
  • Aurora St. Luke's Medical Center
    Milwaukee, Wisconsin 53215, United States
    Recruiting
    • Sudeepta Dandapat · Principal investigator
  • Centre Hospitalier Universitaire de Montpellier
    Montpellier, 34295, France
    Recruiting
    • · Contact+33(0) 467 337 532
    • Vincent Costalat · Principal investigator
  • Fondation Rothschild
    Paris, 75019, France
    Recruiting
    • · Contact(+33) 1 48 03 68 29
    • Michel Piotin · Principal investigator
  • Hospital Foch
    Suresnes, 92150, France
    Recruiting
    • · Contact331-462-52526
    • Arturo Consoli · Principal investigator
  • Centre Hospitalier Universitaire de Toulouse
    Toulouse, 40031, France
    Recruiting
    • · Contact0033561772339
    • Christophe Cognard · Principal investigator
  • Semmelweis University Hospital
    Budapest, 1145, Hungary
    Recruiting
    • Sandor Nardai · Principal investigator
  • Hospital Universitario Vall D'Hebron
    Barcelona, 08035, Spain
    Recruiting
    • Alejandro Tomasello · Principal investigator
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
    Recruiting
    • Jordi Blasco · Principal investigator
  • Hospital Clinico San Carlos
    Madrid, 28040, Spain
    Recruiting
    • · Contact699-856-388
    • Manuel Moreu · Principal investigator
  • Hospital Virgen de la Arrixaca
    Murcia, 30120, Spain
    Recruiting
    • Joaquin Zamarro · Principal investigator
  • Hospital Universitario Central de Asturias
    Oviedo, 33011, Spain
    Recruiting
    • Pedro Vega · Principal investigator
  • Aydin University Hospital
    Istanbul, 34295, Turkey (Türkiye)
    Recruiting
    • · Contact+90 532 594 29 33
    • Serdar Geyik · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Aug 2027, 35 months after the start.

Of 80 industry-sponsored interventional studies with no phase under Ischemic Stroke, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 46. This study's planned 35 months is above that.

Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2024
First posted
Apr 17, 2024
StartActual
Sep 9, 2024
Primary completionEst.
Aug 2027
CompletionEst.
Dec 2027
Last update
Dec 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06370182
Lead sponsor
Anaconda Biomed S.L.
Responsible party
Sponsor
First posted
Apr 17, 2024
Start date
Sep 9, 2024
Primary completion
Aug 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Dec 11, 2025

Study contacts

Hendrik Lambert
Contact
athena@anaconda.bio
(404) 277-7280
Tina Cordaro
Contact
athena@anaconda.bio
Adnan Siddiqui, MD, PhD, FAHA
principal investigator · Jacobs School of Medicine & Biomedical Sciences
Santiago Ortega-Gutierrez, MD, MSc, FAHA, FSVIN
principal investigator · University of Iowa

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion